Insmed, ordinary share
INSM, US4576693075
CBONDSウォッチリストで投資を発見、保存、追跡
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
Cbondsウォッチリストを使用すれば、常に投資状況を最新の状態に保ち、意識的な意思決定が可能です!
最も包括的なデータベースを探索
1 000 000
債券
100 000
株
175 910
ETF&投資信託
100 000
インデックス
最も効率的な方法でポートフォリオを追跡
|
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients
...
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders.
|